Stockwinners Market Radar for February 20, 2024 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:23 EST Alat, Carrier Global to partner on climate and energy solutions in Saudi Arabia - Alat, a PIF company, and Carrier Global "announced their commitment to build a cutting-edge manufacturing and R&D facility in Saudi Arabia that will deliver advanced heating, ventilation and air conditioning solutions. The partnership will serve customers in the Kingdom, and its visionary Giga projects, such as NEOM, as well as ensure broader regional - and even global - distribution. Alat was established on February 1, 2023, by His Royal Highness Prince Mohammed bin Salman Abdulaziz Al Saud, Crown Prince and Prime Minister, Chairman of the Board of Directors of Alat. The agreement will leverage Alat's financial strengths and Carrier's technology and manufacturing capabilities to develop made-in-Saudi Arabia intelligent climate solutions, marking the first phase of the partnership with Alat. These offerings will address the continued growth of the HVAC industry in the Middle East and North Africa region, which is expected to become a US$10 billion addressable market by 2030 - and a $334 billion market globally by 2030 - driven by secular trends including urbanization, sustainability and energy solutions, and digital transformation. This market will also provide scale to develop products, such as solutions for district cooling and heating, which could be used globally."

20:08 EST Cathie Wood's ARK Investment bought 383.5K shares of Roku today

19:45 EST Linkage Global discloses Nasdaq listing notice - Linkage Global announced that it received a notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC, stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because it had not timely filed its Annual Report on Form 20-F for the fiscal year ended September 30, 2023 with the U.S. Securities and Exchange Commission. Nasdaq Listing Rule 5250(c)(1) requires listed companies to timely file all required public financial reports with the SEC. The Notice provides that the Company has until April 16, 2024 to submit to Nasdaq a plan to regain compliance with the Nasdaq Listing Rules. If Nasdaq accepts the Company's plan, then Nasdaq may grant the Company an exception of up to 180 calendar days from the due date of the 2023 Annual Report, or until August 13, 2024, to regain compliance. The Notice has no immediate impact on the listing of the Company's securities on Nasdaq.

18:59 EST Crocs director sells $2.01M in common stock - In a regulatory filing, Crocs disclosed that its director Ian Bickley sold 16.8K shares of common stock on February 16th in a total transaction size of $2.01M.

18:49 EST Palo Alto Networks CEO: There is no problem with demand - In an interview on CNBC's Mad Money, Nikesh Arora said there is nothing wrong with the demand side of the business as AI is creating more cyber attacks. "We had the best earnings beat this quarter in a long time," he noted. Arora thinks cybersecurity budgets are still going to increase. The amount of conversations the company is having with CIO's is at an all-time high, he added. He noted that there was a federal spending that didn't materialize in Q2, however, the business is "strong" and he's not worried about the stock price.

18:15 EST Delek US raises quarterly dividend to 24.5c per share form 24c - Delek US Holdings announced that its Board of Directors has approved a 0.5c per share increase in the regular quarterly dividend to 24.5c per share, to be paid on March 8, 2024, to shareholders of record on March 1, 2024.

17:55 EST Beyond spikes 5% after 'active cutomers' returned to YoY growth, revenue view - Shares are currently up 4% in after hours trading to $28.25 per share "Over the last 75 days into my tenure, we have made substantial progress laying the foundation for a high growth, differentiated business model with high customer affinity," said Marcus Lemonis, Executive Chairman of the Board. "Active customers returned to year-over-year growth for the first time in three years, with over 700,000 customers added to our customer file. Our mandate is to grow our customer file, provide a service level that improves retention and minimizes customer returns. We believe that mandate will result in improved margins and profitability through Beyond.com and our core business. Additionally, as we review our assets and investments, we continue to be optimistic about the value of a few of those investments. As part of that review, we are assessing options related to the portfolio to ensure maximum return for our shareholders. It is our goal to achieve $2B of revenue in 2024, and a $3B revenue run rate by the end of 2025. This projected revenue improvement, coupled with improved margins and a reduced expense structure provides a clear path to profitability." "As a team, we are dissatisfied with the Q4 results and have taken steps to grow revenue, improve margins, and reduce our fixed costs," said Adrianne Lee, Chief Financial and Administrative Officer. "In December, we announced $25Mn of annualized cost reductions. Since that time, we have increased our target to $45Mn of annualized expense reduction, freeing up capital to exclusively invest in growth."

17:31 EST Amazon.com to join Dow Jones Industrial Average, replacing Walgreens - S&P Dow Jones Indices will make the following changes to the Dow Jones Industrial Average effective prior to the open of trading on Monday, February 26. Amazon.com (AMZN) will replace Walgreens Boots Alliance Inc. (WBA) in the Dow Jones Industrial Average. Reflecting the evolving nature of the American economy, this change will increase consumer retail exposure as well as other business areas in the DJIA. The index change was prompted by DJIA constituent Walmart Inc.'s (WMT) decision to split its stock 3:1, which will reduce Walmart's index weight due to the price weighted construction of the index. Walmart will remain in the DJIA. Reference Link

17:30 EST Uber to replace JetBlue Airways in Dow Jones Transportation Average - S&P Dow Jones Indices will make the following changes to the Dow Jones Industrial Average and Dow Jones Transportation Average effective prior to the open of trading on Monday, February 26. Uber Technologies Inc. (UBER) will replace JetBlue Airways Corp. (JBLU) in the Dow Jones Transportation Average. This change will help the index gain exposure to the ride sharing industry. The index change was prompted by JetBlue's low weight in the index of less than one-half of one percentage point caused by its low share price. The Dow Jones Transportation Average is a price weighted index, and thus very low-priced stocks have an immaterial impact on the index.

17:26 EST Jianpu Technology discloses that NYSE will apply to delist its ADSs - In a regulatory filing, Jianpu Technology disclosed that on February 20, it was notified by the NYSE that the staff of NYSE Regulation had determined to commence proceedings to delist the American depositary shares, ADSs, of the company, each representing twenty Class A ordinary shares of the company, from the NYSE. Trading in the company's ADSs was suspended immediately. NYSE Regulation reached its decision to delist the company's ADSs pursuant to Section 802.01B of the NYSE's Listed Company Manual because the company had fallen below the NYSE's continued listing standard requiring listed companies to maintain an average global market capitalization over a consecutive 30-trading-day period of at least $15M. The company has a right to a review of this determination by a committee of the board of the NYSE. The NYSE will apply to the SEC to delist the company's ADSs upon completion of all applicable procedures, including any appeal by the company of the NYSE Regulation staff's decision. The company expects its ADSs to be eligible for quotation on an appropriate tier of the OTC Markets. This transition to the OTC Markets will not change the company's obligation to file annual reports and certain other reports with the SEC under the applicable federal securities laws.

17:21 EST Caesars says experienced headwinds in Las Vegas in the quarter - Says experienced headwinds in Las Vegas in the quarter, but had strong year there. Says event calendar is robust in Las Vegas. Says focused sports betting product on overall experience for customers. Says confident can improve hold in 2024. Says partnered with Chippewa Indians on launching second iGaming brand in Michigan. Says Caesars Palace Online launched second half of Q3. Says Caesars Palace Online now has same level of revenue as the business that proceeded it. Comments taken from Q4 earnings conference call.

17:21 EST Osisko Gold sees FY24 GEOs earned 82,000-92,000 - Osisko expects GEOs earned to range between 82,000-92,000 in 2024 at an average cash margin of 97%. The 2024 guidance assumes the commencement of GEOs earned from the CSA Copper Stream from June 15, as well as the commencement of production from G Mining Ventures' Tocantinzinho project and Cardinal Namdini Mining Limited's project later in the year. Osisko's 2024 guidance on royalty and stream interests is largely based on publicly available forecasts from our operating partners. When publicly available forecasts on properties are not available, Osisko obtains internal forecasts from the producers or uses management's best estimate. Osisko expects its portfolio to generate between 120,000 and 135,000 GEOs in 2028. The outlook assumes the commencement of production at The Windfall Mining Group's Windfall and South32 Ltd's Hermosa, amongst others. It also assumes that Capstone Copper Corp's Mantos Blancos will have reached its nameplate capacity following the recent expansion of its activities, as well as increased production from certain other operators that have announced planned expansions, including Alamos Gold Inc.'s Phase 3+ Expansion at Island Gold.

17:05 EST Western Gas Partners trading resumes

17:01 EST Western Midstream issues statement regarding reports of sales process - Western Midstream (WES) is aware of recent news coverage indicating that WES is working towards a sales process. WES has not launched a sales process nor has it engaged bankers or other advisors with a view toward doing so. The company said, "We are aware, as has been publicly stated, that Occidental Petroleum (OXY) has expressed interest in divesting assets. We cannot speak to the composition of the assets Oxy may seek to divest, and any questions regarding Oxy's ownership interest in WES should be directed to Oxy.

17:00 EST Senator Warren urges regulators to block Capital One-Discover deal - U.S. Senator Elizabeth Warren, a Democrat from Massachusetts, said that the proposed merger of Capital One (COF) and Discover (DFS) "threatens our financial stability, reduces competition, and would increase fees and credit costs for American families. This Wall street deal is dangerous and will harm working people. Regulators must block it immediately." Reference Link

16:41 EST Lilium appoints Dominique Decard to head Lilium POWER-ON unit - Lilium has appointed Senior Lilium Executive Dominique Decard to head the eVTOL industry's first Customer Service organization, named Lilium POWER-ON. ...at the Singapore Air Show, the company announced its newly established business unit that will offer the full aircraft manufacturer services portfolio, including training services, maintenance operations, material and battery management and global distribution, flight operations support, ground service equipment, and digital solutions. As regional air mobility accelerates, our partners can rely on Lilium to provide a comprehensive aircraft manufacturer service organization," said Lilium CEO, Klaus Roewe. "The team is focused on enabling seamless, efficient services and support through premium aftermarket products and world-class partners. With an experienced leader like Dominique at the helm, we are confident Lilium POWER-ON will offer outstanding customer service while strengthening Lilium's business." Work began on Lilium POWER-ON, two years ahead of the Lilium Jet's expected entry into service. Lilium already announced a number of partnerships for its services business, including flight training with Lufthansa Aviation Training and FlightSafety International, and global material services with AJW Group, as well as digital aircraft health management solutions with Palantir.

16:40 EST SilverCrest Metals announces FY24 guidance for Las Chispas Operation - SilverCrest Metals announce its 2024 guidance for the Company's Las Chispas Operation located in Sonora, Mexico. The Las Chispas underground will continue its ramp-up through 2024 with a target to exit the year at over 1,050tpd, in line with the Technical Report. The new mining contractor, Dumas Contracting, arrived at site in early February 2024 to begin mobilization, which is expected to continue through Q3. 2024 guidance incorporates assumptions related to the transition of contractors and ramp-up of Dumas. A total of $4.5 million in mobilization charges will be paid over the mobilization period with the expense recognized over the life of the five year contract and reflected in AISC during this time. In 2024, the processing plant will operate at an average of 1,200 tpd except in Q1, 2024 when there is planned maintenance downtime which will reduce plant availability to approximately 85%. This downtime is not expected to impact production in the quarter as ore blending from the underground mine and high-grade stockpile will offset this downtime. Cash Costs are expected to be $9.50-$10.00/oz AgEq sold. This compares to 2024 cash costs forecast in the Technical Report of $9.80/oz AgEq sold and 2023 guidance of $7.50-$8.50/oz AgEq sold. The major variance from 2023 is the inclusion of Dumas mobilization and demobilization of the outgoing contractor. Cash costs are expected to remain relatively consistent throughout 2024. Eric Fier, CEO, commented, "2023 marked a successful first year of commercial production with Las Chispas exceeding its inaugural sales guidance, leading to full repayment of our debt and a $54.4M or 107% increase in treasury assets. Despite continued cost pressures we are proud to be delivering sales and cost guidance that is in line with our 2023 Technical Report. In 2024 we will continue to pursue capital allocation opportunities including exploration, share buybacks, and growth of our bullion holdings."

16:36 EST O-I Glass investing EUR 95M into two French glass packaging sites - O-I Glass announced the company is investing EUR 95M into two of its French glass packaging production facilities. As a continuation of its modernization investment program, these significant investments aim to upgrade the sustainability, flexibility, and productivity of its operations in Gironcourt-sur-Vraine and Reims. This investment is consistent with O-I's recently updated ESG roadmap which is aligned with our previously announced capital spending plan...The O-I plant in Reims is ideally located in the heart of the Champagne vineyards minimizing delivery routes and time to the wineries. The plant delivers champagne bottles to nearby customers with trucks powered by grapeseed and fryer oil resulting in about a 60% CO2 emission reduction compared to diesel fuel and about 80% less fine particles emissions.,, For Walter Ferrer, Managing Director of O-I Glass for Southwest Europe, "these very significant investments are perfectly in line with the global approach adopted by O-I to reinforce our commitment to sustainable development, increase the energy efficiency of our equipment, create more resilient supply chains and constantly seek to improve the working conditions of our teams. They also demonstrate the confidence we have in our facilities in France, and our full commitment to serving our customers, our teams, and the planet."

16:34 EST Vir Biotechnology Chief Medical Officer to step down - Vir Biotechnology "announced that Executive Vice President, and Chief Medical Officer, Phil Pang, M.D., Ph.D., has decided to leave the company at the end of March 2024 to spend more time with his family. The Company has initiated a search for a successor."

16:32 EST Trinity Capital provides $120M equipment financing to Rocket Lab - Trinity Capital (TRIN) announced the commitment of $120M in equipment financing to Rocket Lab (RKLB), a provider of space launch services and advanced satellite technology. The new debt facility from Trinity will be used to fuel Rocket Lab's expansion plans by financing additional manufacturing capacity, testing equipment, and R&D.

16:28 EST Johnson & Johnson: FDA approves sBLA for TECVAYLI for reduced dosing frequency - Johnson & Johnson announced that the U.S. FDA has approved the supplemental Biologics License Application for TECVAYLI for a reduced dosing frequency of 1.5 mg/kg every two weeks in patients with relapsed or refractory multiple myeloma who have achieved and maintained a complete response or better for a minimum of six months. There is a continued unmet need for patients with multiple myeloma and this approval allows increased flexibility in dosing schedule for appropriate patients with a weight-based regimen.

16:26 EST Arvinas announces resignation of CFO Sean Cassidy - Arvinas announced that Sean Cassidy, Chief Financial Officer and Treasurer, will be leaving the company to pursue a new opportunity, effective February 29. The Arvinas board has launched a formal search process to identify Cassidy's permanent replacement. While this search is underway, Randy Teel, Arvinas' current Senior Vice President of Corporate and Business Development, will assume the role of interim Chief Financial Officer and Treasurer.

16:23 EST Community Health falls 12% to $3.55 after Q4 earnings miss

16:22 EST Graphic Packaging to sell paperboard manufacturing facility to Clearwater Paper - Graphic Packaging (GPK) and Clearwater Pape (CLW) announced that Graphic Packaging has signed a definitive agreement to sell its Augusta, Georgia bleached paperboard manufacturing facility to Clearwater Paper. The transaction value is approximately $700M, based on Adjusted EBITDA of approximately $100M. The transaction is subject to regulatory approvals and is currently expected to close in the second quarter of 2024.

16:20 EST IFF to cut dividend 50% to 40c per share - The company announced that its Board of Directors, together with the management team, updated the company's dividend policy, reducing the expected quarterly dividend approximately 50% to 40c per share, implying $1.60 per share annually. With this announcement, the Board of Directors has declared a regular quarterly cash dividend of 40c per share of its common stock, payable on April 10, 2024 to shareholders of record as of March 22, 2024. The company is right-sizing the dividend to enable faster deleveraging of the balance sheet and provide improved financial flexibility. IFF's dividend is an important part of its capital allocation framework, and the Company is committed to providing a competitive yield.

16:19 EST Select Water Solutions sees FY24 CapEx $140M-$160M - John Schmitz, Chairman of the Board, President and CEO, stated, "Looking ahead to 2024, we are targeting net capital expenditures of $140M-$160M, including $10M-$20M of asset sales. This includes approximately $50M-$60M of maintenance capex, with the remaining primarily weighted towards high gross margin, long-term contracted growth capital projects within our Water Infrastructure segment. I am very confident in our strong backlog for both greenfield and brownfield infrastructure system projects and am excited about the new projects we announced today, especially the Thompson Pipeline in the Bakken, which has been a multi-year development effort for the team. Despite recent commodity price and activity volatility, we continue to experience increased demand for new infrastructure development opportunities across all basins as water infrastructure constraints remain a significant challenge for our customers. Furthermore, the strength of our recent financial performance, including the strong free cash flow generated from our Water Services and Chemical Technologies segments, positioned us to fund these newly announced infrastructure projects in addition to a trio of additional strategic acquisitions during the early part of the Q1. Each of these projects and recent acquisitions capitalizes on our existing market leading positions, established infrastructure and customer relationships."

16:18 EST JBT Corp. sees typical seasonality in revenue, earnings in Q1 - For the first quarter of 2024, JBT anticipates typical seasonality in revenue and earnings. JBT expects a revenue split of approximately 47 percent in the first half of 2024 with approximately 53 percent in the second half of 2024 driven by improvement in demand in the North American poultry market. JBT also anticipates margin improvement during each sequential quarter in 2024 as market conditions are expected to improve and strategic sourcing actions flow through to the results.

16:14 EST Matson says 2024 operating income expected to approximate 2023 level

16:12 EST Viper Energy sees Q1 average daily production 25,000 to 25,500 bo/d - Initiating average daily production guidance for Q1 2024 of 25,000 to 25,500 bo/d or 44,750 to 45,500 boe/d, Initiating full year 2024 average daily production guidance of 25,500 to 27,500 bo/d or 45,500 to 49,000 boe/d, As of December 31 there were approximately 787 gross horizontal wells in the process of active development on Viper's acreage in which Viper expects to own an average 1.7% net royalty interest or 13.4 net 100% royalty interest wells; Approximately 762 gros or 20.0 net 100% royalty interest , line-of-sight wells on Viper's acreage that are not currently in the process of active development, but for which Viper has visibility to the potential of future development in coming quarters, based on Diamondback's current completion schedule and third party operators' permits "The fourth quarter wrapped up a milestone year for Viper. For the full year, average oil production increased 13% compared to the previous year while our average share count was reduced by one percent over the same period. As a result of continued strong organic production growth, accretive acquisitions, and an opportunistic share repurchase program, the fourth quarter of 2023 represented the eighth consecutive quarter of increased production per share for Viper Energy," stated Travis Stice, Chief Executive Officer of Viper.

16:10 EST Halozyme sees FY24 royalty revenue $500M-$525M

16:08 EST TrueCar: Goal is to return to $300M in revenue by end of 2026 - "As a reminder, our goal is to return the business to $300M in revenue with 10% free cash flow margin by the end of 2026, implying a compounded annualgrowth rate of 24% from 2023-2026. We believe we can achieve this goal by focusing on the following four building blocks: (1) activate new dealers, (2) limit dealer churn, (3) grow average revenue per dealer through our expanded product offering, and (4) continue to grow our OEM partnerships. Progress against each of these building blocks will take time but should have a compounding effect over the course of the year."

16:06 EST Fubo sues Disney, Fox, Warner Bros. for antitrust practices - FuboTV (FUBO) filed an antitrust lawsuit against The Walt Disney Company (DIS), FOX Corp. (FOX), Warner Bros. Discovery, Inc. (WBD) and their affiliates today, alleging that the vertically-integrated media companies have engaged in a years-long campaign to block Fubo's innovative sports-first streaming business resulting in significant harm to both Fubo and consumers. The complaint alleges that the forthcoming launch of a sports-streaming joint venture steals Fubo's playbook and is the latest example of this campaign. The Company claims that the Defendants have engaged in a long-running pattern of stymying Fubo's sports-first streaming service by engaging in anti-competitive practices. Fubo was founded nine years ago to offer consumers a sports-first package of live TV streaming channels as a less expensive alternative to traditional cable bundles. However, as described in the complaint, "For decades, Defendants have leveraged their iron grip on sports content to extract billions of dollars in supra-competitive profits" by engaging in practices causing consumers to pay more for highly popular sports content and resulting in significant damages to both Fubo and its customers. Fubo's complaint describes the tactics the Defendants have taken to prevent Fubo from competing fairly in the marketplace. Such practices as outlined in Fubo's legal papers include unfair "bundling" - forcing Fubo to carry dozens of expensive non-sports channels that Fubo's customers do not want as a condition of licensing the Defendants' sports channels. Other examples of anti-competitive behavior cited in the complaint include the Defendants charging Fubo content licensing rates that are as much as 30%-50%+ higher than rates they charge other distributors. Defendants also impose non-market penetration requirements (the percentage of total subscribers to which a content package must be sold to or cannot exceed) on Fubo. These actions individually and collectively increase the costs Fubo must pass onto customers. Fubo believes it has incurred billions of dollars in damages as a result of the Defendants' actions. Additionally, Fubo claims the Defendants have restricted Fubo from offering compelling streaming products that consumers would find desirable, despite similar products being offered by other traditional pay TV and streaming services, including the Defendants' own Hulu service. Fubo further alleges that the Defendants' recently announced joint venture is simply the latest coordinated step in the Defendants' campaign to eliminate competition in the sports-first streaming market and capture this market for themselves.

16:06 EST Jianpu Technology Inc - ADR trading halted, news pending

16:03 EST Halozyme announces new $750M share repurchase plan

16:01 EST Phaxiam Therapeutics trading halted, news pending

15:40 EST Western Gas Partners trading halted, news pending

13:51 EST Albertsons drops 1% after Bloomberg report of expected FTC suit - The shares are down 1% to $21.27 in afternoon trading.

12:45 EST KeyCorp has limited exposure to leveraged lending, office, says CEO

12:44 EST KeyCorp well-positioned for future capital requirements, says CEO - Comments taken from the Bank of America Securities 2024 Financial Services Conference.

12:25 EST Cintas acquires Kentucky's SITEX; terms not disclosed - Cintas Corporation has acquired SITEX, a Kentucky-based, family-owned supplier of uniform and facility service programs. "The Sights family has grown SITEX into a strong regional provider of quality apparel and facility service solutions to their customers in the central Midwest," said Scott Garula, President and COO of Cintas' Rental Division. "They've built a successful company with a well-earned reputation for delivering outstanding customer and employee experiences. We look forward to welcoming SITEX's customers and employees to Cintas in the coming months."

12:19 EST Synlogic engaged Ladenburg to assist in strategic review - Synlogic announced that its board has engaged Ladenburg Thalmann as its financial advisor to assist the company in a review and evaluation of strategic options, in consultation with its financial and legal advisors, with the intent to unlock and maximize shareholder value.

12:06 EST Hexcel announces additional $300M share repurchase program - Hexcel said its board approved an additional $300M share repurchase program. The firm added that approximately $65M in Hexcel stock has been purchased year-to-date through February 16.

12:00 EST Vizio rises 14.8% - Vizio is up 14.8%, or $1.41 to $10.94.

12:00 EST Jumia Technologies falls -12.7% - Jumia Technologies is down -12.7%, or -60c to $4.14.

12:00 EST L.S. Starrett Co falls -16.8% - L.S. Starrett Co is down -16.8%, or -$2.23 to $11.07.

11:18 EST Infobird announces 1-for-8 share consolidation and capital reduction - Infobird announced that the extraordinary general meetings of the shareholders held on February 20 approved the proposed 1-for-8 share consolidation of its ordinary shares as well as capital reduction and share capital reorganization. "Beginning with the opening of trading on February 27, 2024, the company's ordinary shares will begin trading on a post-Share Consolidation basis on the Nasdaq Capital Market under the same symbol 'IFBD', but under a new CUSIP number of G47724300. The objective of the Share Consolidation is to enable the company to regain compliance with Nasdaq Marketplace Rule 5550(a)(2) and maintain its listing on the Nasdaq Capital Market," the company stated.

10:47 EST Intel, Cadence Design expand partnership - Intel Foundry Services (INTC) and Cadence Design Systems (CDNS) announced they have expanded their partnership and entered into a multiyear strategic agreement to jointly develop a portfolio of key customized IP, optimized design flows and techniques for Intel 18A technology featuring RibbonFET gate-all-around transistors and PowerVia backside power delivery. "Joint customers will be able to accelerate their SoC project schedules on process nodes from Intel 18A and beyond while optimizing for performance, power, area, bandwidth and latency for demanding AI, HPC and premium mobile applications," the companies stated. "We're very excited to expand our partnership with Cadence to grow the IP ecosystem for IFS and provide choice for customers. We will leverage Cadence's world-class portfolio of leading IP and advanced design solutions to enable our customers to deliver high-volume, high-performance and power-efficient SoCs on Intel's leading-edge process technologies," said Stuart Pann, Intel senior vice president and general manager of IFS.

10:31 EST US Foods to open five new CHEF'STORE locations in 2024 - US Foods Holding Corp. announced its plan to open five new CHEF'STORE locations in 2024. The new stores will be in Beaverton, Ore.; Hampton, Va.; Hickory, N.C.; Sandy Springs, Ga.; and Virginia Beach, Va. The new locations are expected to open in the second half of 2024. "We are thrilled to enhance our store footprint into new areas of the country where we can serve existing and new customers with exceptional value and service, and a vast selection of competitively priced restaurant-quality products and supplies," said Irfan Badibanga, president of CHEF'STORE. "Our continued growth plans support our commitment to serving independent restaurant owners, foodservice operators, and community members with the products they need, exactly when they need them."

10:15 EST Telomir Pharmaceuticals Inc trading resumes

10:05 EST Telomir Pharmaceuticals Inc trading halted, volatility trading pause

10:01 EST BioSig Technologies terminates 'significant number of its employees' - BioSig Technologies announced that it has terminated a significant number of its employees and expects to substantially reduce business operations.

10:00 EST L.S. Starrett Co falls -12.0% - L.S. Starrett Co is down -12.0%, or -$1.60 to $11.70.

10:00 EST Barclays rises 11.0% - Barclays is up 11.0%, or 82c to $8.29.

10:00 EST Home Depot expects macro headwinds in 2024, but at a 'lesser degree' than 2023 - Says consumer is "healthy and engaged," just on smaller projects. Says underpinnings of home improvement market remain strong. Has "neutral look" on housing in 2024. Says "couldn't feel better" about how the company is positioned from an operational standpoint. Says Q4/FY23 gross margin "in line with expectations."

09:57 EST GigaCloud Technology trading resumes

09:52 EST GigaCloud Technology trading halted, volatility trading pause

09:47 EST Holley falls -8.1% - Holley is down -8.1%, or -40c to $4.53.

09:47 EST Westlake falls -11.5% - Westlake is down -11.5%, or -$16.61 to $127.54.

09:47 EST Discover rises 11.3% - Discover is up 11.3%, or $12.47 to $122.96.

09:45 EST Beamr Imaging Ltd trading resumes

09:40 EST Beamr Imaging Ltd trading halted, volatility trading pause

09:38 EST VirnetX resumes trading, shares down 25% after Supreme Court ruling

09:37 EST Evolv says targeted by short sellers, 'corrects misinformation' - Evolv stated in a press release: "Evolv Technology was founded in 2013 as a next-generation physical security company committed to making the world a safer place. Over a decade later, and with the trust of former leaders of the Central Intelligence Agency, Department of Homeland Security, Federal Bureau of Investigation, Department of Defense, New York Police Department, Office of National Intelligence, Transportation Security Administration, and United States Secret Service, the Company has partnered with hundreds of seasoned security professionals as valued customers. They have vetted and selected Evolv as part of their safety plans due to its performance attributes and track record of balancing accurate detection with a positive security experience for patrons - not because of any advertisement or marketing campaign. Many of these professionals test Evolv products in their operating environment before deployment. Evolv is proud to say that its Express solution has been used to screen over 1 billion visitors, and is used to detect, on average, hundreds of firearms every day across its rapidly growing customer base. Over the past year, Evolv believes it has been the target of a short seller campaign, coordinating with certain media outlets, who are incentivized to discredit the company, misrepresent facts, and promote misinformation. Short sellers essentially bet on, and profit from, a drop in a company's share price." Reference Link

09:34 EST MicroCloud Hologram Inc trading halted, volatility trading pause

09:32 EST VirnetX trading halted, volatility trading pause

09:29 EST Splash Beverage awarded new distribution within Terrible's Convenience - Splash Beverage Group announces it has been awarded new distribution within Terrible's Convenience. Starting this month Copa di Vino single-serve wine will be available in all 115 Terrible's convenience stores in the greater Las Vegas area. This expansion will offer four of Copa di Vino's varietals to the high-traffic chain's shoppers. Robert Nistico, CEO of Splash, said, "This is a great retailer win, now made possible by the company's ardent focus on building a distribution network capable of reaching these key chains which supports our strategic direction."

09:26 EST ParaZero expands collaboration with Vayu Aerospace Corporation - ParaZero Technologies announced it has expanded its collaboration with Vayu Aerospace Corporation, a US-based drone original equipment manufacturer and subsidiary of Alpine 4 Holdings Nasdaq. Boaz Shetzer, Chief Executive Officer of ParaZero commented, "We are glad to strengthen our partnership with Vayu, an innovator in autonomous drone technology. We have many successes from around the world in aiding our customers to achieve regulatory approvals for advanced operations using our SafeAir parachute systems. As we move forward integrating our SafeAir system from the design stage of Vayu's cutting-edge VTOLs, we are setting new standards in drone safety and functionality."

09:15 EST ARS Pharmaceuticals announces results from repeat dosing study of neffy - ARS Pharmaceuticals announced topline results from its clinical study comparing repeat doses of neffy to repeat doses of epinephrine intramuscular injection, as requested by the FDA with and without nasal allergen challenge conditions. "We are very pleased with the topline results from our repeat dose study of neffy under nasal allergen challenge conditions, which we believe will address FDA's requests in their Complete Response Letter and support the approval of neffy for the treatment of Type I allergies, including anaphylaxis," said Richard Lowenthal, Co-Founder, President and CEO of ARS Pharma. "The study objective was to compare twice dosing with epinephrine injection and twice dosing with neffy under normal conditions and after nasal allergen challenge. The results show that the neffy pharmacokinetic and pharmacodynamic profile is greater than or similar to intramuscular injection, the comparator FDA requested for this study. In particular, repeat dosing in the same nostril was greater in exposure than dosing once in each nostril and greater than injection on both PK exposures and PD response at all time points, which may help inform labeling and instructions for use. With these results, we are completing the necessary work to submit our response to FDA in the next couple of months. We look forward to working with the Agency in our efforts to make neffy available to patients as soon as possible."

09:12 EST HUMBL, AFL launch digital ticketing program on blockchain - HUMBL and the Arena Football League, AFL, announced the launch of a ticketing program using digital wallets and blockchain technology, starting first with the Oregon BlackBears team, with an ownership group led by current New York Giants Outside Linebacker and former Oregon Ducks star, Kayvon Thibodeaux. "A major issue in primary and secondary ticketing is secure authentication, sales, and tracking, while maintaining the privacy of the user. This innovative HUMBL Tickets program solves these issues through the use of digital wallets and blockchain technology," said HUMBL CEO Brian Foote.

09:11 EST Target partners with designer Diane von Furstenberg for spring collection - Target announced a limited-time only collection with Diane von Furstenberg, offering the brand's styles as well as fresh takes on categories like activewear and tabletop. The more than 200-piece assortment will span women's, girls' and baby apparel and accessories, plus beauty and home decor, starting at $4, with most items under $50. Also new for Target's limited-time only collaborations, the collection will offer made-to-order furniture starting at $300. The Diane von Furstenberg for Target collection is a collaboration between the fashion designer and her granddaughter, Talita von Furstenberg, and will be available to shop beginning Saturday, March 23, on Target.com and in most Target stores, while supplies last.

09:09 EST Datasea establishes joint venture to enter 5G market in China - Datasea announced that, on December 22, 2023, Guozhong Times, a subsidiary of the Chinese operating company contractually controlled by the company, established a joint venture company in China with new partner Shenzhen Yiyun Technology. The joint venture company, Datasea Yiyun Shenzhen Digital, has been formed in an attempt to further penetrate the 5G multimodal communications sector by leveraging Artificial Intelligence and combining Datasea's technology and service capabilities with Yiyun Technology's digital technology marketing, promotion and 5G operations capabilities. Datasea holds 66% total of the equity of DataSea Digital and Yiyun Technology holds a 34% ownership position. DataSea Digital, the new joint venture company, will serve as the core business carrier of Datasea's AI based 5G multimodal communication services.

09:09 EST LPL Financial launches planning, investing solutions - LPL Financial LLC announced the launch of its expanded High-Net-Worth Services from LPL Business Solutions. This new offering empowers LPL's more than 22,000 financial advisors in delivering an elevated experience and personalized guidance to high-net-worth clients who require sophisticated approaches to manage, safeguard and deploy their wealth.

09:08 EST SunPower names Tom Werner as Executive Chairman of the Board - SunPower announced Tom Werner as Executive Chairman of the Board, effective Feb. 19, 2024. Werner previously served as SunPower's CEO and Chairman of the Board for nearly 18 years. After stepping down as CEO, he served in board and investor roles at H2U Technologies, Inc., Mainspring Energy, Flo, Wolfspeed, VIA Sciences, and Kanin. Before joining SunPower, Werner was CEO at Silicon Light Machines, Inc., an optical solutions subsidiary of Cypress Semiconductor Corporation.

09:05 EST BIO-key receives $1.5M pre-paid, two-year software subscription order - BIO-key International announced that a long-term financial services customer has executed a two-year, pre-paid $1.5 million agreement for the ongoing use and expanded deployment of BIO-key's biometric customer identification technology. The agreement follows continued strong growth in client enrollments by the customer over eight years since its first deployment. The BIO-key system streamlines and enhances security for the client identification process for over 25 million clients and contemplates approximately 12% annual growth in users over the next year.

09:04 EST Allison Transmission's VC arm makes strategic investment in Niron Magnetics - Allison Ventures, Allison Transmission's venture capital arm, announces its strategic investment in Niron Magnetics, a pioneering company in the field of sustainable non-rare earth permanent magnets. This investment marks a significant milestone in the advancement of clean energy solutions and the reduction of reliance on critical materials. "Niron Magnetics is excited to have Allison Ventures as a strategic partner," said Jonathan Rowntree, Chief Executive Officer, Niron Magnetics. "Their expertise and network in commercial-duty propulsion solutions will be instrumental in accelerating the adoption of our Clean Earth Magnet technology and expanding our market reach." Niron Magnetics has developed a breakthrough technology that enables the production of powerful permanent magnets without the need for rare earth elements. With an extensive patent portfolio, Niron Magnetics is poised to revolutionize the magnet industry and address the challenges associated with the global supply chain of rare earth elements. The strategic partnership between Allison Ventures and Niron Magnetics addresses the growing demand for sustainable and environmentally friendly solutions in commercial-duty mobility. Allison Ventures intends to back the commercialization and expansion of Niron's non-rare earth magnet technology, alongside other prominent leaders in the automotive industry, by participating in Niron Magnetics' funding round announced ...."

09:04 EST Avidity Biosciences' candidate for DMD designated Rare Pediatric Disease by FDA - Avidity Biosciences announced that the FDA has granted Rare Pediatric Disease designation to AOC 1044, the company's investigational therapy for the treatment of Duchenne muscular dystrophy, or DMD, in people living with mutations amenable to exon 44 skipping - DMD44 -. AOC 1044 is being assessed in the Phase 1/2 EXPLORE44 trial for people living with DMD44 and is the first of multiple AOCs the company is developing for DMD. In addition to receiving Rare Pediatric Disease Designation, AOC 1044 has been granted Orphan Designation by the FDA and the EMA, and Fast Track Designation by the FDA. DMD is a rare genetic condition that is characterized by progressive muscle damage and weakness due to the loss of dystrophin protein that typically starts at a very young age. Currently, there are no therapies approved targeting exon 44.Avidity plans to provide a first look at AOC 1044 data in people living with DMD44 in 2H 2024.

09:02 EST AbbVie CEO Richard Gonzalez to retire, Robert Michael to succeed - AbbVie announced that its board of directors has unanimously selected Robert Michael, AbbVie's current president and COO, to succeed Richard Gonzalez as the company's CEO. Gonzalez, who has served as CEO since the company's formation in 2013, will retire from the role of CEO and become executive chairman of the board of directors, effective July 1, 2024. Additionally, the board has appointed Michael as a member of the board of directors effective July 1, 2024.

08:52 EST Fractyl Health appoints Conaway to board of directors - Fractyl Health announced the appointment of Samuel Conaway to its Board of Directors. Conaway's background in the commercialization of medical technologies and leadership in new product launches will provide valuable insight and experience as Fractyl Health advances through pivotal clinical studies for T2D and weight loss maintenance and continues its ongoing pilot launch and real-world registry study of Revita in Germany.

08:51 EST Constellation Brands appoints Baldwin as new independent board chair - Constellation Brands announced the election of Christopher Baldwin of CVC Advisors, a leading global private markets manager, to serve as a member of Constellation's board of directors, as well as his appointment as non-executive chair of the company's board, each effective March 1, 2024.

08:50 EST CISO Global receives valuation of more than $50M for IP solutions - CISO Global announces the independent valuation of its initial IP Solutions Portfolio by a global leader in valuation, corporate finance, and restructuring. This valuation includes four IP solutions - Skanda7 Breach Assessment Tool, CISO Edge Cloud Security Platform, CHECKLIGHT Endpoint Security Monitoring, and DISC VPN. The new offerings are representative of the company's push into delivering software-first solutions. "This valuation is representative of our commitment to our clients, is unparalleled, and we continue to innovate by delivering high value, software-first solutions based on AI, ML and advanced algorithms," said David Jemmett, CEO of CISO Global. "By leveraging the latest technology advances coupled with our threat intel team, we are providing unique and actionable intelligence to our clients. These solutions are now being deployed and are strengthening the security posture of our clients. CISO Global will continue to disrupt the status quo by delivering new IP already in development."

08:48 EST Bridger Aerospace announces earliest fire season dispatch - Bridger Aerospace Group announced the deployment of a Pilatus PC-12 Multi-Mission Aircraft to Oklahoma to provide aerial intelligence for early-season wildfires. This marks the earliest seasonal deployment of any Bridger Aircraft since the company's inception in 2014.

08:48 EST Capricor Therapeutics announces manufacturing scale-up of CAP-1002 production - Capricor Therapeutics announced the scale-up to expand manufacturing capacity of CAP-1002 to its new state-of-the-art manufacturing facility, intended for commercial use, subject to regulatory approval, located in San Diego. Furthermore, the Company announced that Cohort B of its HOPE-3, Phase 3 clinical study is enrolling rapidly and is expected to complete full enrollment in the second quarter of 2024. "We are extremely pleased with the progress of our manufacturing scale-up efforts in connection with our new San Diego facility which brings us one step closer towards a successful launch of CAP-1002, should we obtain approval, to meet the significant unmet need in this broad and underserved patient population. This facility was designed to be a versatile and cost-effective way to bring CAP-1002 to market efficiently and it is expected that our enhanced manufacturing capacity to increase our supply capabilities and improve our margins," said Linda Marban, Ph.D., Capricor's chief executive officer. "Furthermore, with Cohort A of the HOPE-3 trial being fully enrolled and topline data readout expected in the fourth quarter of 2024, we plan to meet with the U.S. Food & Drug Administration (FDA) with the aim to discuss possible expedited pathways to approval."

08:46 EST Tenax announces global license amendment, expands rights to levosimendan - Tenax Therapeutics announced it has secured global development, commercial, and IP rights to oral and subcutaneous levosimendan for the treatment of pulmonary hypertension with heart failure with preserved ejection fraction. "We are delighted to enter into this important amendment to our license from Orion. We have achieved a key corporate objective by expanding our development, IP, and commercial territory rights for levosimendan beyond North America," said Chris Giordano, President and Chief Executive Officer of Tenax Therapeutics. "By gaining these worldwide rights, we are now positioned to realize a much larger share of this unique and exciting cardiovascular medicine's value, including through the possible establishment of a global strategic alliance." Effects of the amendment: Tenax gains global development, commercial, and IP rights for oral and subcutaneous formulations in PH-HFpEF; Tiered net sales royalty rates, ranging from high single-digit to low-teen percentages, are payable to Orion; Milestones are payable to Orion based on achievement of net sales targets and certain regulatory approvals, including an additional milestone payment due upon regulatory approval in Japan; Improved terms related to transfer price/cost of goods; Tenax's right of first negotiation to commercialize new applications of levosimendan developed by Orion no longer applies to neurological indications, while Tenax retains such right for all other indications.

08:44 EST Casa develops cloud-native solution to extend wireless wireline coverage - Casa Systems (CASA) announced a breakthrough in wireless wireline convergence: a successful deployment of Casa's virtualized 5G Core control plane function on Amazon (AMZN) Web Services using AWS Region, with Casa's virtualized access gateway function and 5G Core user plane function in private cloud. This proof of concept extends WWC capabilities to the hybrid cloud, demonstrating Casa's unrivaled ability to support service providers with a flexible AGF solution with the potential to dramatically lower operators' capital expenditure and operational expenditure and be integrated with Amazon Elastic Kubernetes Service Anywhere on-premises to further automate operations.

08:43 EST Eterna appoints Cicala to board of directors - Eterna Therapeutics announced the appointment of Peter Cicala, JD, to its Board of Directors. Cicala's most recent experience involves advising start-up and venture-backed biotechnology companies through all aspects of drug development and the protection of proprietary technologies, including long-range strategic planning and commercialization of therapeutics.

08:41 EST Vornado announces Avra Group will open new SF Restaurant in The Penn District - Vornado Realty Trust announced that The Avra Group will open its famed Mediterranean restaurant in THE PENN DISTRICT sitting directly atop Penn Station.

08:34 EST Walmart sees CapEx 3%-3.5% of sales for next couple of years

08:33 EST Pixie Dust announces joint development of Rebar Inspection System - Pixie Dust announced the joint development of the Rebar Inspection System, a technology that captures still images of objects measured from a distance, with MAEDA and Accenture Japan. The Rebar Inspection System utilizes Pixie Dust's spatial data platform "Kotowari", an application designed to acquire, store, and utilize special data, comprehensively analyzing various phenomena in space, including digital data. The Rebar Inspection System on-site construction management testing for reinforcing bar arrangement inspections revealed an 80% reduction in shooting time compared to conventional imaging methods. Development will continue with the objective of achieving a nationwide rollout within MAEDA by April 2024.

08:32 EST Ameresco begins ops of renewable gas facility at Republic's Brickyard Landfill - Ameresco (AMRC) announced that it achieved commercial operation at its landfill gas to renewable natural gas plant at Republic Services' (RSG) Republic Services' in Danville, Illinois. The Brickyard facility has a gross nameplate of over 500,000 Dekatherms per year, with the potential to displace the production of traditional fuel sources and is capable of processing 2,000 scfm of raw landfill gas. This renewable energy project serves as a model for innovative solutions in landfill management and paves the way for a more sustainable future. The Brickyard RNG facility captures naturally occurring landfill gas and transforms it into pipeline-grade RNG, a low-carbon transportation fuel. The RNG that is expected to be produced by this facility would reduce over 27,000 tons of carbon dioxide emissions annually if used to displace diesel vehicle fuel, which is equivalent to the carbon sequestered by planting nearly 326,000 acres of forests. This translates to cleaner air, improved public health and a positive impact in the fight against climate change. By capturing and utilizing landfill gas, the Brickyard facility generates renewable energy displacing fossil fuels used in vehicles like gas powered cars and trucks. This not only reduces the country's reliance on finite resources like oil and gas, but also contributes to the circular economy by extracting value from waste and transforming it into a clean energy source. This process reduces greenhouse gas emissions while contributing to a more sustainable future. "At Republic Services, we're committed to supporting decarbonization, and our partnership with Ameresco has helped us accelerate progress toward our 2030 sustainability goals," said Tim Oudman, Republic Services SVP, Sustainability Innovation. "Through the Brickyard RNG facility, we're able to transform naturally occurring biogas into renewable energy for the local community."

08:27 EST Crown Castle founder Ted Miller issues letter to Chairman on director nominees - Crown Castle founder Ted Miller has nominated a slate of four director nominees to the Crown Castle board of directors and sent a letter on behalf of his investment vehicle Boots Capital Management, to Crown Castle Chairman P. Robert Bartolo. Highlights of the letter include: "...Like you, I believe that Crown Castle must be rebooted after the shameful adventure into fiber, which has cost investors tens of billions and turned the global industry-leader into a ridiculed laggard...Crown Castle lacks leadership, expertise, vision and urgency. It needs a plan. The CEO has resigned, the current CFO has resigned and un-resigned, there is a revolving door of fiber leadership, the EVP/COO of Towers has left, a major employee location has been shuttered and reopened, the company still trades at a 15-20% enterprise-value discount to peers, and the share price reflects skepticism about a potential fiber sale and what comes after. Well, we've got a plan...I would serve as Executive Chairman, and Chuck, Tripp and David as directors. We would help the Board and collaborate with both the interim and new CEO to accomplish the following objectives for all stakeholders: Get fiber sold...not one Board member ever asked to see this extensive work...our model anticipates Crown Castle retaining a minority interest..Our models showed that Crown Castle could go all the way to 2050 and never earn back its own cost of capital...There are significant tax benefits, estimated by our accounting advisers at $1B-plus, that expire at the end of 2024...In 2013, Crown Castle owned 40,000 towers and employed 1,400. Today it still owns 40,000 towers and employs 2,200 people across that business line, even after a 750-person reduction...we intend to use digital-twin and AI technology to reduce customer rebalance and rollout times, while reducing service costs by an estimated 40% during the tower lifecycle.Restoring a positive and productive company culture is essential to driving shareholder value...we have a longer-term detailed approach to help customers access new communications infrastructure that captures immense opportunities in edge compute, Internet of Things, satellite connectivity, private networks, public services and autonomous transportation...Delivering materially improved financials. Clearing a fiber transaction, running a tighter organization, and paying down debt has material financial benefits for all shareholders. That includes our projections to: Take AFFO after discretionary CapEx to over $5 per share by 2025, up from its current $3 per share. Take AFFO after Discretionary Capex and Dividend from a $1.3 billion DEFICIT to a positive $200 million. Drive EBITDA Margin per tower from 70% toward 75-80% in line with Crown Castle's peers AMT and SBA. The current dividend is funded with debt and, in my view, is unsustainable. Our plan is to payout 90%, translating to a dividend of $4.62/share in 2025 with annual growth of 6-7%...Reduce total debt to approximately $17B...Pay off all floating rate debt eliminating interest rate exposure for the company...I have never been more excited about an investment opportunity for all stakeholders. It's why I've got real skin in the game -- $100M of capital from myself and select investors - to aid this transformation...the Cooperation Agreement enshrines Elliott as the de facto controller of the Company, with direct influence at the board level and across the committees that control Crown Castle's strategic future. Our fear is that this bargain with Elliott deprived shareholders of what was best for the Company...The company has offered stockholders no explanation for the Board's decision to give Elliott such dominance..There is a straightforward solution to all this: Promptly submit the Cooperation Agreement to a stockholder vote.... To improve the prospects for all Crown Castle shareholders, I have nominated four directors to the board. Myself; Chuck Green...; Tripp Rice...; and David Wheeler..."

08:22 EST Walmart: Holiday sales were better than expected - Cites two record-breaking volume sales days before Christmas.

08:19 EST Coherent announces Mattera to retire as CEO - Coherent announced that Dr. Vincent Mattera, Jr., has informed the Coherent Board of Directors of his intent to retire as CEO following the commencement of employment of his successor. Dr. Mattera's intention to retire does not reflect a dispute or disagreement with the Company. In parallel with today's announcement, the Company is reaffirming the guidance set forth in that certain Shareholder Letter dated as of February 5, 2024, and furnished on such date as an exhibit to a Current Report on Form 8-K filed on that day. Coherent's Board of Directors has retained a leading executive search firm to immediately commence a comprehensive search process, which will include evaluating internal and external candidates, to identify a new CEO to lead the Company into the future. A subcommittee of the Board has been formed to oversee the search process.

08:17 EST Codexis appoints Damha, Lalonde to strategic advisory board - Codexis announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company's Strategic Advisory Board, joining John Maraganore, PhD. This board is now comprised of experts across oligonucleotide synthesis and manufacturing and was established to help guide the Company's strategic direction, providing critical insights to inform the continued development of Codexis' ECO Synthesis manufacturing platform.

08:15 EST Lottery.com announces voluntary dismissal by Woodford of lawsuit - Lottery.com announces that the legal action alleging proxy misstatements filed in federal court by Woodford Eurasia Assets Ltd against Lottery.com and the individual members of the Company's Board of Directors, including Chairman Matthew McGahan, has been voluntarily dismissed without prejudice by Woodford.

08:14 EST Pagaya names Evangelos Perros CFO - Pagaya announced that Evangelos Perros has been named as the company's CFO, effective immediately. Perros, who has served as the company's Interim CFO since November 2023, was previously the company's deputy CFO and Head of Strategic Finance since joining Pagaya in 2021. As both deputy CFO and then interim CFO, he has led the finance organization.

08:13 EST Multi Ways Holdings announces fleet expansion, renewal strategy - Multi Ways Holdings Limited announced its strategic plans for the procurement and renewal of its fleet. This announcement follows the Company's successful acquisition of new equipment in January 2024 and aims to strengthen its market position through an enhanced range of services. As part of its commitment to excellence and customer satisfaction, Multi Ways Holdings Limited has entered into a significant purchase agreement with SANY International Development Limited, a renowned global manufacturer of top-tier construction equipment. The newly acquired equipment includes: SANY Crawler Crane, Model SCS1500A; SANY Crawler Crane, Model SCC1000A-5; SANY Crawler Crane, Model SCC850A-5; SANY Telescopic Crawler Crane, Model SCC800TB-5.

08:12 EST The Oncology Institute, Carrum Health announce partnership - The Oncology Institute announced its partnership with Carrum Health. This collaboration aims to provide high-quality, cost-effective breast cancer care to patients in TOI's Las Vegas, Nevada market, with plans for further expansion into additional markets in the coming year. Through employers, Carrum Health will offer patients a comprehensive bundled package for breast cancer care, covering two years treatment, including chemotherapy, office visits, and symptom management through TOI. The partnership will focus on patients with non-metastatic breast cancer patients in Las Vegas. TOI will expand its patient base by having access to the Carrum Health network.

08:11 EST Medtronic to exit ventilator product line, combine remaining PMRI businesses - Medtronic has decided to exit its ventilator product line and retain and combine the remaining patient monitoring and respiratory interventions, or PMRI, businesses into one business unit called acute care and monitoring, or ACM. The company said exiting the increasingly unprofitable ventilator product line and combining the remaining businesses allows for increased investment in ACM with a focus on profitable growth. Medtronic will continue to honor existing ventilator contracts and expects that existing manufacturers, who account for the majority of the market, can meet customer demand for new ventilators moving forward.

08:09 EST Cunova to become public through SDCL EDGE Acquisition Corporation merger - Cunova and SDCL EDGE Acquisition Corporation announced that they have entered into a definitive business combination agreement that is expected to result in cunova becoming a publicly listed company on the NYSE. Headquartered in Osnabruck, Germany, cunova is a global producer of copper alloy products and related services and solutions for a diverse array of end markets including casting, maritime, industrial and energy. Under the terms of the proposed business combination agreement, cunova will be indirectly acquired by a publicly-listed, successor entity of SDCL EDGE Acquisition Corporation. Also as part of the proposed business combination, cunova will acquire KME Aerospace from KME Group. The combined company is expected to be listed on the NYSE. Paragon Partners, the current majority shareholder of cunova through its vehicle The Paragon Fund III GmbH & Co. geschlossene Investment KG, is expected to exit cunova as a result of the proposed business combination, and KME Group is expected to become the majority shareholder of cunova. At closing, the combined company is expected to have a pro-forma enterprise value of approximately $736M comprised of pro forma net debt of $289M and an equity value of approximately $447M. Existing SEDA shareholders and any potential investors agreeing to commit to any equity transaction that may be completed prior to the closing of the proposed business combination are expected to own approximately 39.9% of the shares outstanding of the combined company and KME Group is expected to own the approximate remaining 60.1%. These estimates are subject to certain assumptions as well as market conditions and the final transaction structure. The business combination values cunova and KME Aerospace at an enterprise value of approximately 9.4 times cunova's pro forma 2023 Adjusted EBITDA of $78M. The board of SEDA and the shareholders of cunova have approved the proposed business combination subject to customary closing conditions. The closing conditions include, but are not limited to, obtaining all required regulatory approvals, the approval of the shareholders of SEDA, securing minimum cash of $140M, refinancing cunova's current debt, and the registration statement to be filed in connection with the proposed business combination being declared effective by the SEC. Assuming satisfaction of all closing conditions, the proposed business combination is expected to close in the second quarter of 2024.

08:08 EST Transcode Therapeutics reports publication of U.S. patent application - TransCode Therapeutics, reported publication of United States Patent Application titled, "Nanoparticles and Template Directed RIG-I Agonist Precursor Compositions and Uses Thereof For Cancer Therapy." The application describes compositions and methods to treat cancer using a novel class of immunotherapy inspired by the innate immunity of mammalian cells against microbes. This novel type of immunotherapy targets molecules called retinoic acid-inducible gene I -like receptors. RLRs are key RNA sensors that can be activated for the treatment of cancer using synthetic RNAs that mimic viral infection, directing the immune response against cancer. There is no assurance that any patent will issue from this application.

08:07 EST Harmony Biosciences' pitolisant designated Orphan Drug in Prader-Willi syndrome - Harmony Biosciences announced that the FDA has granted Orphan Drug designation to pitolisant for the treatment of Prader-Willi syndrome, or PWS. Approximately 15,000 - 20,000 people in the U.S. are living with PWS, the majority experiencing behavioral symptoms and more than half with excessive daytime sleepiness. In the upcoming Phase 3 registrational TEMPO study, Harmony will assess the safety and efficacy of pitolisant in treating EDS and behavioral disturbances in PWS, anticipated to begin in Q1.

08:05 EST PepGen receives U.S. Fast Track designation for PGN-EDODM1 - PepGen announced that the U.S. Food and Drug Administration, FDA, has granted Fast Track designation to PGN-EDODM1, an investigational candidate for the treatment of myotonic dystrophy type 1, DM1. "Receiving Fast Track designation from the FDA for PGN-EDODM1 is a significant milestone in our efforts to deliver a potentially transformative therapy to the DM1 community," said James McArthur, Ph.D., President and CEO of PepGen. "Patients with DM1 currently have no available treatment options that target the root cause of the disease, which leads to progressive neuromuscular symptoms and reduction in life expectancy. Following robust preclinical data, we are now evaluating PGN-EDODM1 in the ongoing FREEDOM-DM1 Phase 1 trial and expect to report preliminary data later this year. We believe that PGN-EDODM1 has the potential to be disease-modifying and improve outcomes for patients living with DM1."

08:04 EST Enphase Energy expands Solargraf platform - Enphase Energy announced key improvements and new features for Solargraf, its cloud-based design, proposal, and permitting software platform. The Solargraf platform is used by solar installers to create system proposals and design documents for residential and commercial customers.

08:03 EST LyondellBasell acquires mechanical recycling ssets in California - LyondellBasell has acquired mechanical recycling assets and properties containing rigid plastics recycling processing lines from PreZero, a global recycling leader and waste management service provider. The transaction includes leasing the processing facility in Jurupa Valley, Calif., which has a production capacity of approximately 50 million pounds per year for recycled materials. LYB plans to operate its newly-acquired mechanical recycling plant in California to manufacture post-consumer recycled resins using plastic waste feedstock. LYB will offer these recycled polymers under its CirculenRecover brand, part of the company's Circulen portfolio of products that enable the circular economy. LYB expects to commence operations at its new facility in 2025.

08:02 EST 60 Degrees Pharmaceuticals to sponsor pre-clinical studies of Tafenoquine use - 60 Degrees Pharmaceuticals announced it will, through its majority-owned subsidiary 60P Australia Pty Ltd, sponsor a series of animal studies to investigate whether single dose parenteral administration of tafenoquine exhibits efficacy against Candida spp, including Candida auris. C. auris, a strain of fungal yeast, is an emerging pathogen that poses risk of serious infection in the bloodstream and elsewhere, especially in hospitalized patients. The study will be conducted by Monash University in Melbourne, Australia, beginning in the second quarter of 2024. Results are expected by the end of 2024. "The rapid transmission of Candida auris in healthcare facilities is a very real threat and the need for a safe, effective treatment option is becoming more urgent every day," said 60 Degrees Pharmaceuticals Chief Executive Officer and President, Geoff Dow. "This important study could certainly yield valuable insights into how tafenoquine may be used toward that end. We are pleased to serve as the study sponsor working with Monash University and look forward to reviewing results in coming months."

07:51 EST Methanex provides update on issues at Geismar 3 - Methanex Corporation announced that commercial production of its new 1.8 million tonne methanol plant, Geismar 3, in Geismar, Louisiana has been delayed due to complications that occurred in the autothermal reformer during the late stages of the initial start-up process. This issue required the ATR to be cooled and brought to a safe state where teams could conduct detailed inspections of the vessel. Upon completing initial inspections, it has been determined that there is significant damage to a large number of supporting refractory bricks in the vessel which will require replacement. The specialty formed refractory bricks require time to procure and, as a result, management believes commercial production could be delayed up to the end of the third quarter of 2024. The investigation and planning to rectify the issue is ongoing and management is exploring all avenues to accelerate the repair time. Based on the preliminary findings of its root cause analysis, management believes that this issue relates to complications in the initial start-up process and is not a plant design or construction issue. Management believes that the total capital cost will not significantly exceed the upper end of the capital cost guidance of $1.30 billion.

07:46 EST Beyond announces key leadership changes - Beyond, owner of Bed Bath & Beyond, Overstock, and other online retail brands designed to unlock your home's potential, announced significant changes to its executive team. The Executive Chairman and Board of Directors approved the following changes, effective today: Chandra Holt is joining the company as Chief Executive Officer, Bed Bath & Beyond; Dave Nielsen has been appointed to Chief Executive Officer, Overstock; Adrianne Lee, Chief Financial Officer, has taken on an expanded role as Chief Financial & Administrative Officer. As the company - which rebranded from Overstock.com to Beyond in November - continues to evolve, these executive changes were designed to position both the Bed Bath & Beyond and Overstock brands for growth and success into the future.

07:42 EST Vitalhub UK expands healthtech portfolio into Middle East - VitalHub announces the expansion of its digital healthcare portfolio into the Middle East, via a new strategic partnership with Abu Dhabi Health Data Services, an Abu Dhabi-based premier digital healthcare solutions organization and a strategic catalyst for advancing healthcare in Abu Dhabi and beyond. The partnership agreement spans five years and will extend to territories including Israel, UAE, Bahrain, and The Hashemite Kingdom of Jordan, with additional coverage in the rest of the Gulf Cooperation Council countries. Dan Matlow, CEO at VitalHub Corp., parent company of VitalHub UK, added: "This partnership underscores our dedication to advancing healthcare technology in the Middle East, empowering organizations with cutting-edge solutions for improved outcomes and efficiency. With ADHDS's support, we, at VitalHub UK, are well-positioned to deliver enhanced value and innovation to the Middle East healthcare landscape. We anticipate transformative outcomes as our collaboration unfolds, reshaping the trajectory of healthcare technology in the region."

07:41 EST Theratechnologies announces publication in Frontiers in Immunology on TH1902 - Theratechnologies announced the publication of a peer-reviewed article in Frontiers in Immunology that enhances understanding of the molecular mechanism of action of sudocetaxel zendusortide, known as TH1902, as a potential anticancer treatment. Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate that targets the sortilin receptor and expedites the internalization and delivery of the cytotoxic payload directly into cancer cells. The article, "Sudocetaxel Zendusortide triggers the cGAS/STING pathway and potentiates anti-PD-L1 immune-mediated tumor cell killing" appears in the "Cancer Immunity and Immunotherapy" section of the February issue of the journal. It reports on preclinical research in which sudocetaxel zendusortide induced complete and prolonged tumor regression in a triple-negative breast cancer-derived xenograft tumor model and demonstrated tumor regression associated with growth inhibition and immune cell infiltration in a "cold" murine tumor model. Additionally, combining sudocetaxel zendusortide with an anti-PD-L1 checkpoint inhibitor led to increases in tumor growth inhibition and median animal survival.

07:37 EST Evaxion announces completion of initial phases of collaboration with MSD - Evaxion Biotech (EVAX) announces the successful completion of the initial phases of its vaccine collaboration with MSD (MRK). The vaccine development project combines both organizations' unique capabilities and know-how. Evaxion's Chief Executive Officer Christian Kanstrup expresses enthusiasm, "In September last year, we announced a collaboration with a leading pharma company, and today we are proud to present that this collaborator is MSD. Further, we are excited about the successful conclusion of the vaccine target discovery and design phases of the collaboration and are eagerly awaiting the next phase. We strongly believe that this collaboration will further validate the power of our AI-Immunology platform and contribute to improving lives by designing unique vaccines addressing serious medical conditions." Using Evaxion's proprietary platform, AI-Immunology, Evaxion has identified novel vaccine targets against a bacterial pathogen causing severe health issues. The conclusion of the antigen discovery and design phases marks a significant milestone for the development of the vaccine candidate, EVX-B3.

07:35 EST Matinas BioPharma reaches agreement with FDA for Phase 3 trial of MAT2203 - Matinas BioPharma announces alignment with the U.S. Food and Drug Administration, FDA, on the design of a single Phase 3 registration trial of MAT2203 in patients with invasive aspergillosis who have limited treatment options, the ORLATO trial. The ORALTO trial design is built upon the successful Phase 2 EnACT trial that confirmed MAT2203's efficacy and safety as a step-down and all-oral therapy in HIV patients with cryptococcal meningitis, as well as the Company's ongoing Compassionate/Expanded Use Access Program in individuals suffering from severe invasive fungal infections with no other treatment options. "We are pleased to achieve alignment with the FDA on the design of a single Phase 3 trial to support the registration of MAT2203 for the treatment of invasive aspergillosis in patients with limited treatment options," commented Dr. Theresa Matkovits, Chief Development Officer at Matinas. "We greatly appreciate the opportunity to work collaboratively with the FDA, which was essential for reaching consensus on all critical elements of the registrational path for MAT2203. Importantly, we view ORALTO as a registration trial with a high probability of clinical success given the ongoing positive patient clinical experience in our Compassionate/Expanded Use Access Program, which mirrors the patients to be enrolled in our upcoming Phase 3 registration trial."

07:33 EST Rapt Therapeutics announces clinical hold on studies evaluating zelnecirnon - RAPT Therapeutics announced that the U.S. Food and Drug Administration, FDA, has verbally notified the company that a clinical hold has been placed on the company's Phase 2b trial of zelnecirnon, RPT193, in atopic dermatitis and its Phase 2a trial in asthma. The company expects to receive a formal clinical hold letter from the FDA. The clinical hold determination was based on a serious adverse event of liver failure in one patient in the atopic dermatitis trial, the cause of which is currently unknown but which has been characterized as potentially related to zelnecirnon. Dosing of zelnecirnon has been halted in both clinical trials, as has enrollment of new trial participants. The clinical hold does not apply to RAPT's ongoing trial of tivumecirnon, FLX475, in oncology.

07:32 EST Puyi signs first supplementary agreement with White Group - Puyi announces the signing of first supplementary agreement with Singapore White Group to the framework strategic agreement previously disclosed on February 2, 2024. Pursuant to the Agreement, both parties agree to the following matters: White Group intends to inject assets into Puyi aimed at assisting Puyi in driving its artificial intelligence development and international expansion by setting up new offices in Singapore, Vietnam, Europe, the United States and Hong Kong, allowing Puyi to initiate a new phase of strong growth and achieve the "Highest Performances". White Group and its partnerships will invest up to US$500 million in Puyi through new share subscriptions. The main objective of both parties is to explore investments in various high-quality assets that can help Puyi drive its efforts in artificial intelligence development and better serve its clients, including: An AI Humanoid hardware manufacturer with multiple development facilities throughout the world, including China, Japan, the United States, and Europe. It has world-leading, medical-grade AI Humanoid robots that can be applied in various fields such as medical research, home care, and elderly care. A sports entertainment investment company that holds partnerships with major international sports events in China and globally, and ownership in intellectual properties of several prestigious international sport events in China.

07:31 EST Fanhua announces supplementary agreement with Singapore White Group - FANHUA announces the signing of the first supplementary agreement with Singapore White Group to the framework strategic agreement previously disclosed on February 2, 2024. Pursuant to the agreement, both parties agree to the following matters: 1. White Group will inject assets into FANHUA aimed at assisting FANHUA in driving its artificial intelligence development and international expansion by setting new offices in Singapore, Vietnam, Europe, the United States and Hong Kong. 2. White Group and its partnerships will invest up to US$500 million in FANHUA. 3. The main objective of the parties is to explore investments in high-quality assets

07:20 EST Precision BioSciences in non-exclusive patent license deal with Caribou - Precision BioSciences announced that it had granted Caribou Biosciences (CRBU) a CRISPR genome-editing cell therapy company, a non-exclusive, worldwide license, with the right to sublicense, to one of Precision's foundational cell therapy patent families for use with CRISPR in the field of human therapeutics. The licensed patents and applications relate to Precision's approach for targeted insertion of a sequence encoding an exogenous antigen binding receptor into the T cell receptor alpha constant TRAC gene locus of human T cells via a single gene edit. This approach is proprietary to Precision and results in T cells suitable for allogeneic use. The licensed family, which includes more than 20 granted U.S. and international patents, expires in October 2036. Under the terms of the agreement, Precision will receive an upfront payment and, upon commercialization by Caribou, royalties on net sales of licensed products. In addition, for each occurrence of certain strategic transactions involving Caribou, Precision is eligible to receive a specific tiered milestone payment. This patent family is potentially also available for non-exclusive license to other high-quality partners in the cell therapy space.

07:20 EST Chemomab Therapeutics awarded new patents for CM-101 in Brazil and Israel - Chemomab Therapeutics announced that the Patent Offices in Brazil and Israel have granted new patents for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target that has been shown to play a critical role in the processes that drive diseases involving fibrosis and inflammation. Topline data readout expected midyear 2024. The grant of the patent was published January 2, 2024, with corresponding first to expire claims in 2035. PSC is a potentially lethal condition that lacks any FDA-approved therapies and frequently requires liver transplantation.

07:17 EST SciSparc announces Clearmind filed three patents - SciSparc (SPRC) announced that as part of its ongoing collaboration with Clearmind Medicine (CMND), Clearmind filed three patent applications under the international Patent Cooperation Treaty. The three patent applications refer to novel proprietary combinations of lysergic acid diethylamide, psilocybin, N,N-dimethyltryptamine and Palmitoylethanolamide, the active ingredient of SciSparc's proprietary CannAmide. "We are pleased to continue our ongoing collaboration with Clearmind by expanding the intellectual property portfolio, which is an important asset," said SciSparc's Chief Executive Officer, Oz Adler. "We believe in the added value that CannAmide can offer when combined with various psychedelic compounds that are known for their therapeutics advantages."

07:16 EST Herbalife CEO Michael Johnson purchases 61,725 shares at $8.07 - Herbalife announced that its chairman and CEO, Michael Johnson, purchased 61,725 Herbalife shares in transactions that closed on Friday, February 16. The shares were acquired at an average price of $8.07 per share totaling nearly $500,000.

07:16 EST Walmart says crossed $100B in e-commerce sales - The company said, "Our team delivered a great quarter, finishing off a strong year. We crossed $100 billion in eCommerce sales and drove share gains as our customer experience metrics improved, even during our highest volume days leading up to the holidays. We're proud of the team and excited about building on our momentum as we work to bring prices down for our customers and members."

07:15 EST Celcuity appoints Mayer as Chief Commercial Officer - Celcuity (CELC) announced the appointment of Eldon Mayer as Chief Commercial Officer. Prior to joining Celcuity, Mr. Mayer served as Executive Vice President and Chief Commercial Officer at Eiger Biopharmaceuticals (EIGR)

07:14 EST Silver Spike Investment announces broadening of investment strategy - Silver Spike Investment announced that the board of directors of Silver Spike has unanimously approved an expansion of Silver Spike's investment strategy to permit investments in companies outside of the cannabis and health and wellness sectors that otherwise meet the Company's current investment criteria. While the cannabis sector will continue to be a focus of Silver Spike's investment efforts, Silver Spike believes that the broadened investment strategy will benefit Silver Spike and its stockholders by enabling Silver Spike to take advantage of investment opportunities outside of the cannabis and health and wellness sectors that offer attractive risk-adjusted returns. The investment strategy change is expected to become effective on or about April 22, 2024.

07:13 EST S&P Global to acquire Visible Alpha, terms not disclosed - S&P Global announced an agreement to acquire Visible Alpha, the financial technology provider of deep industry and segment consensus data, sell-side analyst models and analytics from high-quality, exclusive sources. The acquisition will create a premium offering of fundamental investment research capabilities on S&P Global Market Intelligence's Capital IQ Pro platform. The combination of Visible Alpha with S&P Capital IQ Pro, the flagship S&P Global platform for research and analysis across institutional and corporate markets, reflects S&P Global's continued commitment to be the foremost provider in this space. The transaction with Visible Alpha is subject to customary closing conditions, including receipt of certain regulatory approvals. It is expected to close during 2024 and the financial terms of the transaction were not disclosed. The company does not expect these proposed transactions to have a material financial impact to S&P Global Market Intelligence or the company as a whole.

07:12 EST Arvinas announces first-in-human dosing of ARV-102 - Arvinas announced that the first subject was dosed in its Phase 1 clinical trial of ARV-102, the Company's first oral PROTAC protein degrader in development to treat neurodegenerative diseases. In preclinical studies, ARV-102 has been shown to cross the blood-brain barrier and degrade leucine-rich repeat kinase 2, LRRK2, which is a large multidomain scaffolding kinase. Increased activity and expressions of LRRK2 is genetically involved in the pathogenesis of neurological diseases including Parkinson's disease and progressive supranuclear palsy. In non-human primates, orally administered ARV-102 has been shown to reach deep-brain regions and degrade LRRK2 by nearly 90%. The Phase 1 clinical trial of ARV-102 is enrolling healthy volunteers at the Centre for Human Drug Research in Leiden, the Netherlands. The trial will evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of ARV-102, including the evaluation of LRRK2 degradation and exploratory LRRK2 pathway biomarkers.

07:11 EST Silver Spike announces agreement to acquire loan portfolio from Chicago Atlantic - Silver Spike Investment announced that it entered into a definitive agreement with Chicago Atlantic Loan Portfolio for the purchase from CALP of a sizeable portfolio of loans. The Company will acquire the CALP Loan Portfolio in exchange for newly issued shares of the Company's common stock with a net asset value equal to the value of the CALP Loan Portfolio, each determined shortly before closing. The Loan Portfolio Acquisition is consistent with the Company's new, broadened investment strategy, separately announced today. The closing of the Loan Portfolio Acquisition is subject to certain customary closing conditions. Assuming satisfaction of the conditions to the transaction, the Loan Portfolio Acquisition is expected to close in mid-2024.

07:08 EST Walmart to acquire Vizio for $11.50 per share in cash - Walmart (WMT) and Vizio (VZIO) announced they have entered into an agreement for Walmart to acquire Vizio for $11.50 per share in cash, equating to a fully diluted equity value of approximately $2.3B. The transaction is subject to regulatory clearance and other closing conditions specified in the merger agreement. Vizio's board of directors has unanimously approved the transaction. VIZIO stockholders holding approximately 89% of the voting power of VIZIO's outstanding common shares have approved the transaction. No other stockholder approval is required to complete the transaction. VIZIO has the right to terminate the transaction within a 45-day period if, subject to the terms and conditions of the merger agreement, VIZIO receives and accepts a "Superior Offer" as defined in the merger agreement. Upon completion of the transaction, VIZIO's Class A common stock will no longer be publicly listed. Due to certain transaction-related costs associated with the acquisition, including for talent retention and technology integration, Walmart expects the transaction to be slightly dilutive to EPS in the near term. To finance the acquisition, Walmart plans to use cash and/or debt. The transaction is not subject to a financing condition. IRR for this transaction is expected to be ahead of Walmart's reported ROI. Following the completion of the transaction, VIZIO's business will be reported as part of the Walmart U.S. segment.

07:06 EST Voyager Therapeutics reports preclinical activity on tau silencing gene therapy - Voyager Therapeutics announced new data from its two preclinical programs targeting pathological tau for the treatment of Alzheimer's disease. Data on VY-TAU01, Voyager's lead anti-tau antibody candidate, and on Voyager's tau silencing gene therapy program will be presented at the upcoming 2024 International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders, taking place March 5-9, 2024, in Lisbon, Portugal. Tau Silencing Gene Therapy Program: The data demonstrate that a single intravenous administration of one of Voyager's tau silencing gene therapy candidates in mice expressing human tau resulted in broad AAV distribution across multiple brain regions and dose-dependent reductions in tau messenger RNA levels of up to 90%. Based on these data, Voyager has advanced this program into late research and expects to file an investigational new drug application in 2026. VY-TAU01 Anti-Tau Antibody: Voyager also will report new preclinical data demonstrating that VY-TAU01, the Company's lead antibody targeting pathological tau, and Ab-01, its murine surrogate, were well-tolerated and showed favorable pharmacokinetic profiles following IV administration in NHPs and P301S transgenic mice expressing pathological human tau. Voyager continues to anticipate an IND filing for VY-TAU01 in the first half of 2024.

07:04 EST Marimaca Copper appoints Gonzalez as General Counsel, Corporate Secretary - Marimaca Copper welcomes Solange Gonzalez as General Counsel and Corporate Secretary, based in the Company's Santiago, Chile office. Prior to joining Marimaca, Gonzalez served as Executive Legal Manager, M&A and Corporate Finance at the Falabella Group

07:03 EST Walmart to acquire Vizio for $11.50 per share, or about $2.3B in cash

06:51 EST KalVista awarded UK Innovation Passport for sebetralstat - KalVista Pharmaceuticals announced the UK Medicines and Healthcare products Regulatory Agency has awarded the Innovation Passport for sebetralstat, an investigational novel, oral plasma kallikrein inhibitor for the on-demand treatment of hereditary angioedema. The Innovation Passport is the first step in the UK's Innovative Licensing and Access Pathway, which is designed to accelerate a product's time to market and facilitate patient access to innovative medicines.

06:48 EST Equitrans Midstream sees 2024 net income $375M-$455M

06:45 EST Wipro, IBM expand partnership to offer new AI services - Wipro Limited (WIT) announced the launch of Wipro Enterprise Artificial Intelligence-Ready Platform, a new service that will allow clients to create their enterprise-level, fully integrated and customized AI environments. The Wipro Enterprise AI-Ready Platform leverages the IBM (IBM) watsonx AI and data platform, including watsonx.ai, watsonx.data, and watsonx.governance and AI assistants, to deliver to clients an interoperable service that helps accelerate AI adoption. This new service enhances operations with a suite of capabilities spanning across tools, large language models, streamlined processes, and robust governance, and lays the foundation for future industry analytic solutions to be built on watsonx.data and AI. Wipro Enterprise AI-Ready Platform is born out of an expanded multi-year partnership between Wipro and IBM. The expanded partnership brings together the technology and industry expertise of Wipro with leading hybrid cloud and AI innovation from IBM and aims to build joint solutions that help advance the implementation of robust, reliable, integrated, and enterprise-ready AI solutions.

06:38 EST CenterPoint Energy raises 10-year capital plan to $44.5B - Increased the 10-year capital plan through 2030 to $44.5B, a $600M increase through 2030 which includes $100M already deployed in 2023 with the remaining $500M to be invested over the remainder of the decade.

06:28 EST EU new car registrations up 12.1% in January - In January, the EU new car market rebounded from the slowdown experienced in December 2023, with year-on-year car registrations increasing by 12.1% to 851,690 units, the ACEA announced. Notably, the bloc's major markets all saw significant growth, with Germany, Italy, France, and Spain achieving either high single-digit or double-digit gains, the industry group stated. Publicly traded automakers include Ford (F), General Motors (GM), Honda (HMC), Mercedes-Benz Group (DDAIF), Nissan (NSANY), Stellantis (STLA), Tesla (TSLA), Toyota (TM) and Volkswagen (VWAGY). Reference Link

06:23 EST Evolv says SEC initiating investigation - Evolv Technology provided an update on a request received from the U.S. Securities and Exchange Commission, or SEC. The company stated: "Specifically, on Friday, February 16, 2024 the SEC notified the company it was initiating an investigation that was described as a confidential 'non-public, fact finding inquiry.' The company notes the SEC's explicit guidance that the investigation 'should neither be construed as an indication by the Commission or its staff that any violation of law has occurred, nor as a reflection upon any person, entity, or security.' The company is eager to cooperate with the SEC as it is with any regulatory body. The company was contacted by a representative of the media within hours of receiving the SEC's confidential notice seeking comment on an SEC matter. In the interest of transparency, the company has decided to disclose the matter publicly considering attempts by certain media outlets to discredit the company and manipulate the customer markets the company serves. Evolv stands behind its technology and is proud to partner with hundreds of security professionals to add a layer of advanced technology to their safety plan. The company's technology is deployed at over 650 customers across many markets including education, healthcare, professional sports, industrial workplaces, houses of worship and tourist attractions. Prior to purchasing Evolv products, key customer decision makers - many whom often have years of security and technology expertise - typically conduct their own extensive testing in their actual operating environment. Based on these successful testing and validation outcomes, Evolv Express has now been used to screen over 1 billion visitors and is used to identify hundreds of firearms every day across the company's rapidly growing customer base. The company's team includes security professionals who have served in leadership positions in the Central Intelligence Agency, Department of Homeland Security, Federal Bureau of Investigation, Department of Defense, New York Police Department, Office of National Intelligence, Transportation Security Administration, and United States Secret Service."

06:13 EST Acri Capital Acquisition signs business combination agreement with Foxx - Acri Capital Acquisition and Foxx Development, a Texas based consumer electronics and integrated Internet-of-Things solution company, have entered into a definitive business combination agreement pursuant to which a newly established subsidiary of Acri will become a publicly listed company combining Acri and Foxx upon the closing of the transaction contemplated therein. Upon closing, the combined company expects to list its common stock on Nasdaq. Foxx currently sells a range of products including mobile phones, tablets and other consumer electronics devices throughout the U.S. The merger consideration is $50M payable by newly-issued common stock of the combined company valued at $10.00 per share. Additional up to 4,200,000 shares of common stock may be issued to Foxx Stockholders upon achievement of certain financial performance milestones of the combined company for the fiscal years ending June 30, 2024 and June 30, 2025. Following the closing, the Acri stockholders will have approximately 51.98% equity interest in the combined company and the Foxx Stockholders will have approximately 48.02% equity interest in the xombined xompany assuming there is no transaction financing in connection with the Proposed Transaction. If, however, there is a maximum redemption of existing public shareholders of Acri, the Acri shareholders will have approximately 30.13% equity interest in the combined company and the Foxx Stockholders will have approximately 69.87% equity interest in the combined company. The proposed transaction is expected to be completed in Q2 2024.

06:11 EST Metals Acquisition commences trading on ASX - Metals Acquisition Limited is pleased to announce that following completion of its heavily oversubscribed initial public offering in Australia of CDIs, the company has commenced trading on the Australian Securities Exchange under the ticker 'MAC'.

06:09 EST Armada Hoffler raises quarterly dividend 5% to 20.5c per share - Armada Hoffler announced that its Board of Directors declared the cash dividend of 20.5c per common share, representing a 5% increase over the prior quarter's dividend. The first quarter dividend will be paid in cash on April 4 to stockholders of record on March 27.

06:08 EST TRI Pointe sees 2024 home delivery 6K-6,300 homes at average price $645K-$655K - Expects Q1 homebuilding gross margin percentage to be 21.5%-22.5% and anticipates its SG&A expense as a percentage of home sales revenue will be 10.5%-11.5%. Lastly, the company expects its effective tax rate for 2024 to be approximately 26.5%.

06:07 EST TRI Pointe sees Q1 home delivery 1,200-1,400 homes at average price $645K-$655K - Expects Q1 homebuilding gross margin percentage to be 22.0%-23.0% and anticipates its SG&A expense as a percentage of home sales revenue will be 12.0%-13.0%. Lastly, the company expects its effective tax rate for Q1 to be approximately 26.5%.

06:01 EST Cadre to acquire Alpha Safety for $106.5M - Cadre Holdings announced it has entered into a definitive agreement to acquire Alpha Safety Intermediate, LLC, the operating parent of Alpha Safety, a leading nuclear safety solutions company for $106.5M. Founded in 1986, Alpha Safety is a global provider of highly engineered, technical products and services focused on radiation protection and safety in mission-critical operating environments. The transaction is anticipated to close in the first quarter of 2024, subject to the satisfaction of customary closing conditions, and is expected to be funded through available cash on the company's balance sheet and an increase in term debt under its existing credit facility. Houlihan Lokey served as the exclusive financial advisor to Alpha Safety.

05:42 EST Lilium reports PhilJets intent to purchase 10 Lilium Jets, bring eVTOLs to Asia - Lilium and PhilJets announced the signing of a memorandum of understanding at the Singapore Airshow. The agreement includes the intent to purchase 10 Lilium Jets, as well as a future strategic collaboration on the establishment of an eVTOL operation network across the Philippines and other Southeast Asia countries, such as Cambodia. As part of the agreement, Lilium and PhilJets will partner to develop a future service, including the joint definition of routes, city pairs, and passenger demand for an on-demand eVTOL service in the region. Both companies will also identify potential sites, requirements, and partners for landing infrastructure, including the identification of vertiport partners in the region, sharing vertiport specifications and access to Lilium's existing network of charging hardware providers.

05:37 EST SSR Mining provides update on ongoing rescue efforts at Copler mine - SSR Mining provided an update on ongoing rescue efforts at the Copler mine in Turkiye as well as an amendment to the date of the company's full-year financial results. On February 19, Turkish Government authorities chose to temporarily suspend search and rescue activities in order to focus on stabilization of the heap leach area. SSR Mining continues to cooperate fully with all Government requests and is supporting efforts on site. Due to the Copler Incident, SSR Mining will target the release of its fourth quarter and full-year 2023 financial results for after market close on Tuesday, February 27.

05:30 EST Vertical Aerospace awarded $10M in grant funding by UK Government - Vertical Aerospace announced it has been awarded $10M in grant funding by the UK Government, through the Aerospace Technology Institute, or ATI, Program, to develop its next-generation propellers for use on its VX4 aircraft. The project is the third awarded to Vertical by the ATI Program and brings total UK Government grant funding to $47M.

05:23 EST Boeing announces Royal Brunei Airlines purchases four 787 Dreamliners - Boeing and Royal Brunei Airlines announced the airline's purchase of four 787 Dreamliners to renew its widebody fleet. Royal Brunei Airlines' selection of the 787-9 supports the airline's long-term growth strategy, sustainability goals and focus on passenger comfort. Royal Brunei Airlines was the first Southeast Asian carrier to fly the 787 Dreamliner over a decade ago. With this 787-9 order, which was finalized in February and will be posted on Boeing's Orders & Deliveries, the airline can fly more passengers and cargo farther while operating more efficiently.

05:12 EST Elbit Systems awarded $300M contract to supply armored vehicle systems - Elbit Systems announced that it was awarded a contract in an amount of approximately $300M to supply weapon, reconnaissance, driving, and situational awareness systems for approximately 230 armored vehicles, to a European customer. The contract will be performed over a period of six years and includes custom design, production, lifecycle maintenance and complete in-country support.

05:06 EST ChargePoint, AcBel Polytech enter pact to jointly develop EV charging solutions - ChargePoint and AcBel Polytech announced an agreement to jointly develop EV charging solutions. AcBel will begin to co-design hardware for ChargePoint's portfolio of EV charging solutions - bringing products to market faster and at a lower cost, while maintaining ChargePoint's high quality and reliability standards. The agreement expands ChargePoint's existing manufacturing agreement with AcBel. By combining AcBel's 40 years of expertise in power design and Kinpo's electronic manufacturing capabilities, ChargePoint believes the partnership will bolster its research and development capabilities, enabling it to bring new products to market faster and at a lower cost. By harmonizing the processes of engineering, design, development and production with AcBel and Kinpo, ChargePoint will have an end-to-end solution enabling ChargePoint's engineering team to focus on future innovation.